URGN earnings date and last-quarter result: next report 2026-08-06, last quarter miss, P/E -15.29. Updated 2026-07-23.
UroGen Pharma (URGN) Research Hub
UroGen Pharma (URGN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 34.04 USD (-1.30%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -15.29, market cap 2.09B. This hub links to the full technical, earnings and options research available for URGN.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 34.04 USD (-1.30%) |
| 52-week range | 29.46 USD – 50.81 USD |
| Trend regime | Range |
| 14-day RSI | 21.6 (Oversold) |
| Trailing P/E | -15.29 |
| Market cap | 2.09B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for URGN
Covered Call on URGN: how it works, illustrative setup around the real 34.04 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on URGN: how it works, illustrative setup around the real 34.04 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on URGN: how it works, illustrative setup around the real 34.04 USD price, max profit/loss, breakeven and when to use it. Educational.
URGN technical analysis: range, last 34.04 USD, RSI 21.6, 52w range 29.46 USD–50.81 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is URGN in?
UroGen Pharma (URGN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is URGN in an uptrend or downtrend?
As of 2026-10-26, URGN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is URGN's trailing P/E ratio?
URGN's trailing P/E is -15.29, with a market cap of 2.09B. See the earnings research page for full valuation detail.
When does URGN next report earnings?
URGN is next scheduled to report earnings on 2026-08-06.